Name: Clarity Pharmaceuticals (CU6) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CU6

Clarity Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Clarity Pharmaceuticals is a clinical-stage company specializing in radiopharmaceuticals, focusing on theranostic products that combine therapy and imaging. Utilizing its proprietary SAR Technology, Clarity aims to improve cancer treatment outcomes with its Targeted Copper Theranostic platform. The company is positioned as a leader in next-generation radiopharmaceuticals, offering products that provide high accuracy and precision in cancer treatment.

Short position

short percentage8.24%

reported shorts30.8M

shares on issue373.081M

Clarity Pharmaceuticals (ASX:CU6) has 8.24% of its shares on issue reported as short positions as of 24 Aug 2026, or about 30,751,668 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.58 percentage points. Its highest recorded short interest was 9.68% in July 2025. CU6 is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.